The second finding in our study was an overexpression of LAG-3 on the CD4+ lymphocyte surfaces of the microenvironment of Hodgkin lymphoma, in patients exposed to anti-PD-1 immunotherapy. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.